General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Pancreatic Neuroendocrine Tumors
Last updated October 11, 2013
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Thromboembolic events prevention, (atrial fibrillation)
Last updated October 10, 2013
Status:
Concluded with an LOI
Manufacturer:
Shire Pharma Canada ULC
Indication:
Fabry Disease
Last updated September 24, 2013
Status:
Concluded with an LOI
Manufacturer:
Astellas Pharma Inc.
Indication:
Metastatic Castration-Resistant Prostate Cancer
Last updated September 23, 2013
Status:
Concluded with an LOI
Manufacturer:
Sanofi Genzyme Canada
Indication:
Fabry Disease
Last updated September 20, 2013
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Myelofibrosis
Last updated September 3, 2013
Status:
Negotiations were not pursued
Manufacturer:
Allergan Inc.
Indication:
Hypertension
Last updated August 22, 2013
Aloxi IV (palonosetron hydrochloride)
Status:
Negotiations were not pursued
Manufacturer:
Eisai Limited
Indication:
Nausea and vomiting (chemotherapy induced) prevention
Last updated August 21, 2013
Aloxi (palonosetron hydrochloride)
Status:
Negotiations were not pursued
Manufacturer:
Eisai Limited
Indication:
Nausea and vomiting (chemotherapy induced) prevention
Last updated August 21, 2013
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Pancreatic Neuroendocrine Tumors
Last updated August 14, 2013